Literature DB >> 22797806

Attempted suicide under high dose dopaminergic therapy including apomorphine.

Walter Struhal1, Michael Guger, Stephanie Hödl, Sok-Chu Ung, Michael Bach, Gerhard Ransmayr.   

Abstract

Impulse control disorder during continuous subcutaneous apomorphine treatment (CAI) was recently reported. We describe a 54-year-old patient with familial Parkinson's disease, who after initiation of CAI in addition to high dose levodopa and amantadine, developed impulse control disorder (major financial loss related to risky transactions and self-medication), psychosis and depression, which lead up to attempted suicide. To our knowledge, this is the first case of attempted suicide under apomorphine treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22797806     DOI: 10.1007/s00508-012-0202-5

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  9 in total

1.  Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Paolo Barone; Werner Poewe; Stefan Albrecht; Catherine Debieuvre; Dan Massey; Olivier Rascol; Eduardo Tolosa; Daniel Weintraub
Journal:  Lancet Neurol       Date:  2010-05-07       Impact factor: 44.182

2.  Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease.

Authors:  T Soulas; J-M Gurruchaga; S Palfi; P Cesaro; J-P Nguyen; G Fénelon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-04-10       Impact factor: 10.154

3.  Impulse control disorders and depression in Finnish patients with Parkinson's disease.

Authors:  Juho Joutsa; Kirsti Martikainen; Tero Vahlberg; Valerie Voon; Valtteri Kaasinen
Journal:  Parkinsonism Relat Disord       Date:  2011-10-07       Impact factor: 4.891

4.  Prospective prevalence of pathologic gambling and medication association in Parkinson disease.

Authors:  V Voon; K Hassan; M Zurowski; S Duff-Canning; M de Souza; S Fox; A E Lang; J Miyasaki
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

5.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

Review 6.  Impulse control disorders and pathological gambling in patients with Parkinson disease.

Authors:  William Stamey; Joseph Jankovic
Journal:  Neurologist       Date:  2008-03       Impact factor: 1.398

Review 7.  Continuous dopaminergic stimulation--from theory to clinical practice.

Authors:  Angelo Antonini
Journal:  Parkinsonism Relat Disord       Date:  2007-08-16       Impact factor: 4.891

Review 8.  When a Parkinson's disease patient starts to hallucinate.

Authors:  Werner Poewe
Journal:  Pract Neurol       Date:  2008-08

9.  Cross-national prevalence and risk factors for suicidal ideation, plans and attempts.

Authors:  Matthew K Nock; Guilherme Borges; Evelyn J Bromet; Jordi Alonso; Matthias Angermeyer; Annette Beautrais; Ronny Bruffaerts; Wai Tat Chiu; Giovanni de Girolamo; Semyon Gluzman; Ron de Graaf; Oye Gureje; Josep Maria Haro; Yueqin Huang; Elie Karam; Ronald C Kessler; Jean Pierre Lepine; Daphna Levinson; Maria Elena Medina-Mora; Yutaka Ono; José Posada-Villa; David Williams
Journal:  Br J Psychiatry       Date:  2008-02       Impact factor: 9.319

  9 in total
  2 in total

Review 1.  Anhedonia and Suicide.

Authors:  Randy P Auerbach; David Pagliaccio; Jaclyn S Kirshenbaum
Journal:  Curr Top Behav Neurosci       Date:  2022

2.  Galphimia glauca and Natural Galphimines Block Schizophrenia-Like Symptoms Induced with Apomorphine and MK-801 in Mice.

Authors:  Mayra Alejandra Santillán-Urquiza; Maribel Herrera-Ruiz; Alejandro Zamilpa; Enrique Jiménez-Ferrer; Rubén Román-Ramos; Elian Yuritzi Alegría-Herrera; Jaime Tortoriello
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-21       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.